Aurobindo Pharma Ltd

Aurobindo Pharma will hold a meeting of the Board of Directors of the Company on 5 August 2026.

The approval follows a GMP inspection conducted by ANVISA from 11 May to 15 May 2026. The inspection covered the facility's biological API and sterile product manufacturing operations. The scope of the inspection included four biosimilar products and assessed the mammalian and microbial drug substance manufacturing facility, prefillable syringe and vial filling facility, packaging and labelling operations, as well as quality control testing and release laboratories. The company said CuraTeQ's drug substance and drug product GMP facility is already certified by the European Medicines Agency (EMA) and the World Health Organization (WHO). The ANVISA approval further strengthens the company's regulatory credentials and enhances its ability to supply biosimilar products to Brazil and the broader Latin American market. Aurobindo Pharma is engaged in the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services. The company reported a 2% rise in consolidated net profit to Rs 921.26 crore on a 4.4% increase in net sales to Rs 8,751.50 crore in Q4 FY26 over Q4 FY25. The counter slipped 2.65% to Rs 1,538.60 on the BSE. Powered by Capital Market - Live

Aurobindo Pharma announced that PT Aurogen Pharma Indonesia, a wholly owned stepdown subsidiary of the Company, has incorporated a new wholly owned subsidiary company by the name of PT Auro Pharm Indonesia, in Indonesia. The object of incorporation of this wholly owned step down subsidiary is to undertake manufacturing operations in Indonesia.

Aurobindo Pharma has completed the transfer of the Company's domestic branded generic pharmaceutical formulations products business, as a going concern to Auropharm with effect from 01 July 2026.

Aurobindo Pharma USA Inc., (APUSA), a wholly owned subsidiary of Aurobindo Pharma, announced the successful completion of its acquisition of Lannett Company, Inc., USA (Lannett), from Lannett Seller Holdco, Inc., following receipt of approval from the U.S. Federal Trade Commission on 18 June 2026. Effective 29 June 2026, Lannett has become a wholly owned subsidiary of APUSA and will operate as Lannett Company LLC. The integration process will commence immediately, with a strong emphasis on ensuring uninterrupted access to critical medications, maintaining trusted relationships with partners, and supporting employees throughout the transition.

The inspection, conducted between 22 June and 26 June 2026, covered the facility that manufactures active pharmaceutical ingredients (APIs) and pharmaceutical formulation intermediates. The inspection concluded with two observations. The company said it will respond to the observations within the stipulated timeline. Aurobindo Pharma reiterated its commitment to maintaining the highest quality manufacturing standards and said it will keep the stock exchanges informed of any further developments related to the inspection. The official announcement was made on Saturday, 27 June 2026. Aurobindo Pharma is engaged in the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services. The company reported a 2% rise in consolidated net profit to Rs 921.26 crore on a 4.4% increase in net sales to Rs 8,751.50 crore in Q4 FY26 over Q4 FY25. The counter advanced 1.15% to Rs 1,572.85 on the BSE. Powered by Capital Market - Live

The inspection, conducted between 22 June and 26 June 2026, covered the facility that manufactures active pharmaceutical ingredients (APIs) and pharmaceutical formulation intermediates. The inspection concluded with two observations. The company said it will respond to the observations within the stipulated timeline. Aurobindo Pharma reiterated its commitment to maintaining the highest quality manufacturing standards and said it will keep the stock exchanges informed of any further developments related to the inspection. Aurobindo Pharma is engaged in the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services. The company reported a 2% rise in consolidated net profit to Rs 921.26 crore on a 4.4% increase in net sales to Rs 8,751.50 crore in Q4 FY26 over Q4 FY25. The counter advanced 1.65% to end at Rs 1,554.95 on the BSE. Powered by Capital Market - Live

Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) conducted an inspection at Auroactive Pharma (a wholly owned subsidiary of the Company), which manufactures Active Pharmaceutical Ingredients (API) & Pharmaceutical Formulation Intermediates, situated at Sy Nos 231, 285 to 291, Sancham Village, Ranasthalam Mandal, Srikakulam District, 523 409, Andhra Pradesh, from 22 June 2026, to 26 June 2026. The inspection concluded with 2 observations and will be responded to within the stipulated time.

The transaction, valued at $250 million on a cash-free, debt-free basis, including normalized working capital, is expected to be completed before the end of June 2026. Lannett, a Pennsylvania-based generic pharmaceutical company, focuses on the development and commercialization of a diversified portfolio of complex, non-opioid controlled substances. The acquisition is expected to significantly strengthen Aurobindo USA's presence in this segment while adding a U.S.-based manufacturing facility to its operations. The deal includes Lannett's manufacturing facility in Seymour, Indiana, has the capacity to scale production to approximately 4 billion doses annually, strengthening Aurobindo USA's domestic manufacturing footprint. This enhanced capacity aligns with U.S. policy priorities aimed at improving supply chain resilience and increasing domestic pharmaceutical production. According to the company, the acquisition is expected to be immediately accretive to the Aurobindo Group's earnings per share. It is also anticipated to generate cost efficiencies, SG&A synergies and operational integration benefits while expanding the company's portfolio of complex generics and controlled substances, supporting long-term growth. Swami S. Iyer, chief executive officer of Aurobindo Pharma USA, said, 'This acquisition represents a highly compelling strategic and financial opportunity for Aurobindo USA. It accelerates our revenue growth, strengthens our U.S.-based manufacturing capabilities, and enhances our position in complex, non-opioid controlled substances. We are confident it will deliver immediate earnings accretion while creating long-term value for our shareholders through operational synergies and pipeline expansion. We are pleased to welcome the Lannett team and look forward to leveraging our combined strengths to expand and ensure reliable access to critical medications for patients.' Tim Crew, Lannett Company's chief executive officer, said, 'We are delighted to be joining forces with Aurobindo. As one of the nation's oldest generic pharmaceutical companies, Lannett has a proud history of helping patients access affordable medicines. Aurobindo's market reach and resources will help make our portfolio of medicines even more affordable and accessible for patients everywhere. Our board and owners extend their sincere appreciation to the outstanding teams at both companies whose professionalism, commitment, and hard work have successfully brought us to this important moment. We look forward to building on all that has come before as we begin a bright and exciting next chapter.' Aurobindo Pharma is engaged in the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services. The company reported a 2% rise in consolidated net profit to Rs 921.26 crore on a 4.4% increase in net sales to Rs 8,751.50 crore in Q4 FY26 over Q4 FY25. The counter shed 0.92% to Rs 1,484 on the BSE. Powered by Capital Market - Live

Aurobindo Pharma USA, Inc. (Aurobindo USA), a wholly owned subsidiary of the Company, today announced that it has received approval from the U.S. Federal Trade Commission (FTC) to proceed with the acquisition of Lannett Company LLC (Lannett). The transaction, valued at $250 million on a cash-free, debt-free basis and inclusive of normalized working capital, is expected to close before the end of June 2026. Lannett, a Pennsylvania-based generic pharmaceutical company, specializes in the development and commercialization of a diversified portfolio of complex, non-opioid controlled substances. The acquisition will significantly expand Aurobindo USA's product offering in this segment while adding a U.S.-based manufacturing facility to its network. Lannett's manufacturing site in Seymour, Indiana, has the capacity to scale production to approximately 4 billion doses annually, strengthening Aurobindo USA's domestic manufacturing footprint. This enhanced capacity aligns with U.S. policy priorities aimed at improving supply chain resilience and increasing domestic pharmaceutical production. The transaction is expected to be immediately accretive to Aurobindo Group's earnings per share. In addition to near-term financial benefits, the acquisition is anticipated to generate meaningful cost efficiencies, SG&A synergies, and operational integration advantages. It will also enhance the company's portfolio with a differentiated pipeline of complex generics and controlled substances, supporting sustainable long-term growth.